<p>Panel A shows the pharmacokinetics for twice-a-day intake for 5 days and the panel B once a day intake for 10 days. The black line represents the for drug-sensitive virus and the dashed line the for resistant virus. The s were converted from to ng/mL for this figure.</p
We conducted a 2-sample pharmacokinetic study of oselta-mivir in 12 premature infants. Oseltamivir 1...
<p>Oseltamivir phosphate (OP) is absorbed at rate and converted into oseltamivir carboxylate (OC) at...
Estimated mitigation of influenza transmission by baloxavir and oseltamivir according to treatment i...
<p>Each panel represents the variation of efficacy depending on the therapy initiation time relative...
<p>Area under the concentration versus time curve (AUC<sub>0t</sub>) is indicated. Values represent ...
<p>Plasma concentrations (µg/l) are depicted for each individual patient in time (h). Individual pat...
The effects of loading doses and probenecid coadministration on oseltamivir pharmacokinetics at four...
The aims of this study were to compare the pharmacokinetics of oseltamivir and oseltamivir carboxyla...
Neuraminidase inhibitors are the mainstay of anti-influenza treatment. Oseltamivir is the most widel...
Obesity is an independent risk factor for mortality in patients infected with pandemic influenza A v...
Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the inf...
<p> and represent the effectiveness of oseltamivir on drug-sensitive and drug-resistant virus, resp...
Neuraminidase inhibitors are the mainstay of anti-influenza treatment. Oseltamivir is the most widel...
Oseltamivir and oseltamivir carboxylate concentrations were measured in venous plasma, venous blood,...
<p>(A) Survival time according to molecular viral load at D7; (B) molecular viral load at D7 accordi...
We conducted a 2-sample pharmacokinetic study of oselta-mivir in 12 premature infants. Oseltamivir 1...
<p>Oseltamivir phosphate (OP) is absorbed at rate and converted into oseltamivir carboxylate (OC) at...
Estimated mitigation of influenza transmission by baloxavir and oseltamivir according to treatment i...
<p>Each panel represents the variation of efficacy depending on the therapy initiation time relative...
<p>Area under the concentration versus time curve (AUC<sub>0t</sub>) is indicated. Values represent ...
<p>Plasma concentrations (µg/l) are depicted for each individual patient in time (h). Individual pat...
The effects of loading doses and probenecid coadministration on oseltamivir pharmacokinetics at four...
The aims of this study were to compare the pharmacokinetics of oseltamivir and oseltamivir carboxyla...
Neuraminidase inhibitors are the mainstay of anti-influenza treatment. Oseltamivir is the most widel...
Obesity is an independent risk factor for mortality in patients infected with pandemic influenza A v...
Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the inf...
<p> and represent the effectiveness of oseltamivir on drug-sensitive and drug-resistant virus, resp...
Neuraminidase inhibitors are the mainstay of anti-influenza treatment. Oseltamivir is the most widel...
Oseltamivir and oseltamivir carboxylate concentrations were measured in venous plasma, venous blood,...
<p>(A) Survival time according to molecular viral load at D7; (B) molecular viral load at D7 accordi...
We conducted a 2-sample pharmacokinetic study of oselta-mivir in 12 premature infants. Oseltamivir 1...
<p>Oseltamivir phosphate (OP) is absorbed at rate and converted into oseltamivir carboxylate (OC) at...
Estimated mitigation of influenza transmission by baloxavir and oseltamivir according to treatment i...